Foundation Medicine, Inc.
One Kendall Square
201 articles with Foundation Medicine, Inc.
Roche’s investment is aimed at supporting the development of Freenome’s colorectal cancer detection technology.
FoundationOne®CDx Receives FDA Approval as a Companion Diagnostic for BRAF Inhibitor Therapeutics in Melanoma
Foundation Medicine, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx.
Foundation Medicine, Inc. today announced the appointment of Dymeka Harrison, MBA, as its Chief Commercial Officer.
Science 37® and Foundation Medicine Partner to Enable Interventional Home-Based Clinical Trials in Oncology
Science 37 and Foundation Medicine today announced a collaboration to enable decentralized clinical research in oncology that will optimize recruitment and enrollment, improve patient retention, and expand access to precision cancer care.
8/6/2021Biopharma and life sciences companies strengthen their leadership teams with these Movers & Shakers.
Agrawal will oversee and expand collaborations with BioPharma organizations to support and accelerate the development of innovative cancer treatments
Foundation Medicine Collaborates on Research Published in The New England Journal of Medicine That Identifies Resistance to KRAS Inhibitors and Underscores Need for Novel Therapeutic Strategies
Foundation Medicine, Inc. and its collaborators announced results from a Dana-Farber Cancer Institute-led study that used genomic testing, including Foundation Medicine’s liquid-based comprehensive genomic profiling test, FoundationOne®Liquid CDx, among several assays, to investigate resistance mechanisms in 38 patients with cancer treated with a KRAS G12C inhibitor.
Foundation Medicine Launches FoundationOne®Tracker ctDNA Monitoring Assay for Research Use in Partnership with Natera
Foundation Medicine, Inc. and Natera, Inc., announced the launch of the research use version of FoundationOne®Tracker, Foundation Medicine's personalized circulating tumor DNA monitoring assay.
New Study Results Presented by Foundation Medicine and Collaborators at ASCO21 on Ancestry-Based Disparities in Prostate Cancer Care Underscore Importance of Equitable Access to Precision Medicine Advances
Data sourced from clinico-genomic database revealed lower rates of early genomic testing use and clinical trial enrollment among men of African ancestry compared to those of European ancestry
Foundation Medicine and Collaborators to Share New Data During ASCO21 Showcasing the Clinical Utility of Genomic Testing and Its Role in Informing Treatment Decisions Across Ancestry and Disease Type
Foundation Medicine, Inc . today announced that the company and its collaborators will present a total of 29 studies, including two clinical science symposia presentations and two poster discussions, at the 2021 American Society of Clinical Oncology Virtual Scientific Program (ASCO21) from June 4-8.
Foundation Medicine, Inc. today announced the appointment of Brian Alexander, M.D., M.P.H., as chief executive officer, effective April 6, 2021. Dr. Alexander previously served as Foundation Medicine’s chief medical officer since 2019 and brings with him years of experience as a radiation oncologist at Dana-Farber/Brigham
Foundation Medicine and InformedDNA® Collaborate to Improve Access to Genetic Counseling for Advanced Cancer Patients
Partnership improves access to genetic counseling services when suspected hereditary cancer gene variant is identified through Foundation Medicine’s tumor testing
New Study from Foundation Medicine and Collaborators Further Demonstrates the Clinical Utility of Blood-Based Comprehensive Genomic Profiling in Patients with Advanced Prostate Cancer
Results from the study assessing concordance of genomic alterations identified by liquid and tissue biopsy published in Clinical Cancer Research and to be presented at the American Society of Clinical Oncology 2021 Genitourinary Cancers Symposium
Foundation Medicine, Inc. announced the transition of Cindy Perettie, Chief Executive Officer, to Roche Diagnostics to lead the Molecular Lab Solutions business headquartered in Pleasanton, California effective April 6, 2021.
Guardant Health is taking Roche-owned Foundation Medicine to court over a patent dispute for their liquid biopsy technology, further heating up the rivalry between the two cancer detection companies.
Foundation Medicine Enters into Patent Licensing and Technology Agreement with TwinStrand Biosciences
Foundation Medicine announced it has entered into a non-exclusive agreement to license two foundational patent families from TwinStrand Biosciences, a next-generation DNA sequencing technology company based in Seattle.
Foundation Medicine Expands Indication for FoundationOne®Liquid CDx to be used as a Companion Diagnostic for LYNPARZA®
Foundation Medicine Expands Indication for FoundationOne ® Liquid CDx to be used as a Companion Diagnostic for LYNPARZA ® Foundation Medicine’s pan tumor liquid biopsy test is now FDA-Approved to identify patients with BRCA1, BRCA2 and/or ATM alterations in metastatic castration-resistant prostate cancer who may be appropriate for treatment with LYNPARZA
FoundationOne®CDx Receives FDA-Approval as a Companion Diagnostic for VITRAKVI®(larotrectinib) to Identify Patients with NTRK Fusions Across All Solid Tumors
FoundationOne ® CDx Receives FDA-Approval as a Companion Diagnostic for VITRAKVI®(larotrectinib) to Identify Patients with NTRK Fusions Across All Solid Tumors CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Foundation Medicine, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a companion diagnostic for VITRAKVI® (larotrectinib), which is currently FDA-approved for the treatment o
Foundation Medicine and Takeda Announce Collaboration To Develop FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for Takeda’s Late-Stage Lung Cancer Portfolio
Companion diagnostics will be developed to identify patients with NSCLC that harbor ALK fusions and EGFR Exon20 insertion mutations to match patients with appropriate targeted therapies from Takeda
FDA Approves Foundation Medicine's FoundationOne®Liquid CDx, a Comprehensive Pan-Tumor Liquid Biopsy Test with Multiple Companion Diagnostic Indications for Patients with Advanced Cancer
FDA Approves Foundation Medicine's FoundationOne ® Liquid CDx, a Comprehensive Pan-Tumor Liquid Biopsy Test with Multiple Companion Diagnostic Indications for Patients with Advanced Cancer FDA Approval Includes Companion Diagnostic Claims for Rubraca ® (rucaparib), the First PARP Inhibitor Approved in a Prostate Cancer Setting, and Three Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer FoundationOne Liquid CDx Analyzes More Than 300 Genes a